Skip to content

Effect of Liposomal Bupivacaine for Thoracic Paravertebral Block on Postoperative Analgesia in Patients With Multiple Rib Fractures

Effect of Liposomal Bupivacaine for Thoracic Paravertebral Block on Postoperative Analgesia in Patients With Multiple Rib Fractures

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114294
Enrollment
Unknown
Registered
2025-12-10
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rib fracture

Interventions

Trial group:Bupivacaine liposome 20ml(266mg)

Sponsors

Beijing Jishuitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Subjects who can understand the procedures and methods of the clinical trial, provide full informed consent, and voluntarily participate, with the informed consent form signed by the subject or their legal guardian. 2. Patients scheduled to undergo internal fixation surgery for multiple rib fractures under general anesthesia. 3. Age: 18–64 years. 4. ASA: I–III

Exclusion criteria

Exclusion criteria: 1. BMI >= 35 kg/m^2 or BMI <= 15 kg/m^2; 2. Bilateral rib fractures; 3. Combined multiple injuries: such as limb injuries, cranial or cerebral injuries, thoracoabdominal combined injuries, etc.; 4. History of chronic pain (pain lasting more than three months other than the current surgical indication, such as trauma, herpes zoster, trigeminal neuralgia, etc.); 5. Pregnant or lactating women, currently breastfeeding, or who have given birth within the past six months even without artificial breastfeeding; 6. Underwent major surgery within 3 months (90 days) prior to dosing, or underwent surgery that may significantly affect the pharmacokinetics or safety evaluation of the study drug; 7. Excessive alcohol or drug abuse, long-term use of opioid medications; 8. History of allergy to local anesthetics; 9. Coagulation dysfunction; 10. Infection at the puncture site; 11. Severe cardiovascular, respiratory, or neurological diseases; 12. Inability to understand or use the pain scale prior to surgery; 13. Patient refusal.

Design outcomes

Primary

MeasureTime frame
The VAS score 48 hours after the operation;

Secondary

MeasureTime frame
VAS score;Area under the pain intensity score-time curve within 72 hours postoperatively (AUC 0–72 h);Ultrasound assessment of diaphragmatic excursion and respiratory function (tidal volume, forced vital capacity);Blood gas analysis;Mean arterial pressure;Heart rate;Oxygen saturation;Respiratory rate;Quality of postoperative recovery;Opioid Consumption;Length of Stay;Satisfaction Score for Postoperative Analgesia;Nerve block–related complications;

Countries

China

Contacts

Public ContactZhao Yaoping

Beijing Jishuitan Hospital, Capital Medical University

524825706@qq.com+86 135 2173 2670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026